PPLPHARMAPharmaceuticals
Piramal Pharma Ltd — Profit & Loss Statement
₹136.54
+1.77%
Piramal Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -11.90 Cr | -19.43 Cr | -1.46 Cr | 1.43 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.30 | 0.30 | 0.22 | — |
| Normalized EBITDA | 1.69K Cr | 1.43K Cr | 899.13 Cr | 1.25K Cr | — |
| Total Unusual Items | -39.66 Cr | -64.77 Cr | -4.88 Cr | 6.35 Cr | — |
| Total Unusual Items Excluding Goodwill | -39.66 Cr | -64.77 Cr | -4.88 Cr | 6.35 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 91.13 Cr | 17.82 Cr | -186.46 Cr | 375.96 Cr | — |
| Reconciled Depreciation | 816.34 Cr | 740.56 Cr | 676.69 Cr | 586.18 Cr | — |
| Reconciled Cost Of Revenue | 3.57K Cr | 3.26K Cr | 3.00K Cr | 2.68K Cr | — |
| EBITDA | 1.65K Cr | 1.37K Cr | 894.25 Cr | 1.26K Cr | — |
| EBIT | 832.57 Cr | 626.24 Cr | 217.56 Cr | 673.76 Cr | — |
| Net Interest Income | -411.01 Cr | -436.57 Cr | -342.54 Cr | -197.57 Cr | — |
| Interest Expense | 417.93 Cr | 446.95 Cr | 337.71 Cr | 188.78 Cr | — |
| Interest Income | 10.58 Cr | 11.92 Cr | 1.64 Cr | 0.68 Cr | — |
| Normalized Income | 118.89 Cr | 63.16 Cr | -183.04 Cr | 371.04 Cr | — |
| Net Income From Continuing And Discontinued Operation | 91.13 Cr | 17.82 Cr | -186.46 Cr | 375.96 Cr | — |
| Total Expenses | 8.38K Cr | 7.64K Cr | 7.08K Cr | 6.11K Cr | — |
| Rent Expense Supplemental | 32.91 Cr | 31.59 Cr | 32.10 Cr | 28.25 Cr | — |
| Diluted Average Shares | 133.07 Cr | 128.35 Cr | 121.27 Cr | 121.70 Cr | — |
| Basic Average Shares | 132.33 Cr | 128.11 Cr | 121.27 Cr | 121.70 Cr | — |
| Diluted EPS | 0.68 | 0.14 | -1.54 | 3.09 | — |
| Basic EPS | 0.69 | 0.14 | -1.54 | 3.09 | — |
| Diluted NI Availto Com Stockholders | 91.13 Cr | 17.82 Cr | -186.46 Cr | 375.96 Cr | — |
| Net Income Common Stockholders | 91.13 Cr | 17.82 Cr | -186.46 Cr | 375.96 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 91.13 Cr | 17.82 Cr | -186.46 Cr | 375.96 Cr | — |
| Minority Interests | 0.00 | 0.00 | — | — | — |
| Net Income Including Noncontrolling Interests | 91.13 Cr | 17.82 Cr | -186.46 Cr | 375.96 Cr | — |
| Net Income Continuous Operations | 91.13 Cr | 17.82 Cr | -186.46 Cr | 375.96 Cr | — |
| Tax Provision | 323.51 Cr | 161.47 Cr | 66.31 Cr | 109.02 Cr | — |
| Pretax Income | 414.64 Cr | 179.29 Cr | -120.15 Cr | 484.98 Cr | — |
| Other Non Operating Income Expenses | 75.65 Cr | 128.72 Cr | 110.14 Cr | 235.12 Cr | — |
| Special Income Charges | -48.71 Cr | -64.37 Cr | -7.44 Cr | -16.78 Cr | — |
| Other Special Charges | -1.44 Cr | 63.79 Cr | 0.48 Cr | 0.54 Cr | — |
| Write Off | 0.00 | 0.58 Cr | 0.00 | 1.16 Cr | — |
| Impairment Of Capital Assets | 50.15 Cr | 0.00 | — | 0.00 | 37.43 Cr |
| Net Non Operating Interest Income Expense | -411.01 Cr | -436.57 Cr | -342.54 Cr | -197.57 Cr | — |
| Total Other Finance Cost | 3.66 Cr | 1.54 Cr | 6.47 Cr | 9.47 Cr | — |
| Interest Expense Non Operating | 417.93 Cr | 446.95 Cr | 337.71 Cr | 188.78 Cr | — |
| Interest Income Non Operating | 10.58 Cr | 11.92 Cr | 1.64 Cr | 0.68 Cr | — |
| Operating Income | 678.64 Cr | 462.03 Cr | -47.97 Cr | 365.16 Cr | — |
| Operating Expense | 4.81K Cr | 4.39K Cr | 4.08K Cr | 3.43K Cr | — |
| Other Operating Expenses | 1.04K Cr | 978.44 Cr | 880.44 Cr | 704.16 Cr | — |
| Depreciation And Amortization In Income Statement | 816.34 Cr | 740.57 Cr | 676.69 Cr | 586.18 Cr | — |
| Depreciation Income Statement | 816.34 Cr | 740.57 Cr | 676.69 Cr | 586.18 Cr | — |
| Research And Development | 97.13 Cr | 100.67 Cr | 86.36 Cr | 128.34 Cr | — |
| Selling General And Administration | 605.46 Cr | 566.88 Cr | 555.38 Cr | 476.83 Cr | — |
| Selling And Marketing Expense | 349.27 Cr | 304.13 Cr | 323.69 Cr | 285.62 Cr | — |
| General And Administrative Expense | 256.19 Cr | 262.75 Cr | 231.69 Cr | 191.21 Cr | — |
| Rent And Landing Fees | 32.91 Cr | 31.59 Cr | 32.10 Cr | 28.25 Cr | — |
| Gross Profit | 5.49K Cr | 4.85K Cr | 4.03K Cr | 3.79K Cr | — |
| Cost Of Revenue | 3.57K Cr | 3.26K Cr | 3.00K Cr | 2.68K Cr | — |
| Total Revenue | 9.06K Cr | 8.11K Cr | 7.03K Cr | 6.47K Cr | — |
| Operating Revenue | 9.06K Cr | 8.11K Cr | 7.03K Cr | 6.47K Cr | — |
| Restructuring And Mergern Acquisition | — | 0.00 | 6.96 Cr | 15.08 Cr | 45.19 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Piramal Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.